Impact of sirolimus treatment for refractory kaposiform hemangioendothelioma with exacerbation of the disease 10 years after initial diagnosis.

Sakata, Naoki; Suenobu, So-Ichi; Okano, Munehiro; Ueda, Satoshi; Kimura, Masatomo; Takemura, Tsukasa

Sakata, Naoki; Suenobu, So-Ichi; Okano, Munehiro; Ueda, Satoshi; Kimura, Masatomo; Takemura, Tsukasa.

Afiliação

Sakata N; Department of Pediatrics, Kinki University Faculty of Medicine, Osaka-Sayama, Japan.
Suenobu SI; Division of General Pediatrics and Emergency Medicine, Department of Pediatrics, Oita University Faculty of Medicine, Oita, Japan.
Okano M; Department of Pediatrics, Kinki University Faculty of Medicine, Osaka-Sayama, Japan.
Ueda S; Department of Pediatrics, Kinki University Faculty of Medicine, Osaka-Sayama, Japan.
Kimura M; Department of Pathology, Kinki University Faculty of Medicine, Osaka-Sayama, Japan.
Takemura T; Department of Pediatrics, Kinki University Faculty of Medicine, Osaka-Sayama, Japan.

Rare Tumors ; 10: 2036361318776185, 2018.

Article em En | MEDLINE | ID: mdl-29872523

Palavras-chave

KasabachMerritt phenomenon; Sirolimus; kaposiform hemangioendothelioma; mammalian target of rapamycin; molecular targeting drug

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Revista: Rare Tumors Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Japão

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google